Homepage
Author:
Vor Biopharma
Posted Date:
June 8, 2026
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
Vor Biopharma
June 8, 2026
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
Vor Biopharma
June 8, 2026
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Biopharma
June 1, 2026
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
Vor Biopharma
May 28, 2026
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
Vor Biopharma
May 14, 2026
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Vor Biopharma
May 13, 2026
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Biopharma
May 4, 2026
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Biopharma
April 1, 2026
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Vor Biopharma
March 30, 2026
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
Vor Biopharma
March 30, 2026
1
2
Next
